BrightGene Bio-Medical Technology (688166.SH): BGM0504 Tablets Receive Drug Clinical Trial Approval Notice

Zhitong Finance APP News, BrightGene Bio-Medical Technology (688166.SH) announced that its wholly-owned subsidiary, BrightGene Pharmaceutical (Suzhou) Co., Ltd. (referred to as "BrightGene Pharmaceutical"), recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, agreeing to conduct clinical trials of BrightGene Pharmaceutical's BGM0504 tablets in adult patients with type 2 diabetes.